by Elec23 | Dec 3, 2025 | News&events
VisMederi is pleased to announce the establishment of VisMederi America, a new company based in Cleveland that marks a strategic milestone in the Group’s expansion into the United States. The new entity aims to strengthen VisMederi’s international presence,...
by Elec23 | May 30, 2025 | News&events
Influenza has been a major global problem for centuries. Although vaccination can reduce the health and economic consequences of an influenza epidemic, current vaccines are far from perfect. Many research teams around the world have worked to create an effective...
by Elec23 | Feb 24, 2025 | News&events
VisMederi has expanded its testing portfolio with cutting-edge pseudo-viral platforms, which are critical tools for examining immunogenicity and developing vaccines against emerging infections. These new technologies enable us to test immune responses in a safe and...
by Elec23 | Oct 8, 2024 | News&events
For those wishing to fully immerse themselves in the serological techniques required by regulatory agencies including the FDA, EMA, and PMD for the licensing and approval of viral vaccines, a 12-week program has been developed by Trialect and VisMederi Foundation....
